Answers are grounded in this paper and cite their sources.
Pulmonary diseases are prevalent globally. N6-methyladenosine (m6A) modification is a type of RNA modification found in eukaryotes that significantly regulates different biological processes. Several studies have underscored the function of m6A RNA methylation in modulating immunological responses, inflammatory pathways, and its potential use as a diagnostic, prognostic, or therapeutic target for human lung cancer and lung injury, establishing it as a prospective study domain in pulmonary diseases. Considering the dynamic regulation of m6A methylation in many lung diseases and its influence on crucial RNAs, targeting the regulators of m6A modification may represent a viable therapeutic approach. This review systematically elucidates new advancements about the functions of m6A modification in pulmonary diseases and emphasizes its prospective use in the amelioration and therapy of these conditions.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: